Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCerillion Regulatory News (CER)

Share Price Information for Cerillion (CER)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,585.00
Bid: 1,570.00
Ask: 1,600.00
Change: 30.00 (1.89%)
Spread: 30.00 (1.911%)
Open: 1,590.00
High: 1,620.00
Low: 1,585.00
Prev. Close: 1,590.00
CER Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Further concentrate purchase

1 Oct 2007 07:02

Celtic Resources Holdings PLC01 October 2007 1 October 2007 Celtic Resources Holdings Plc ("Celtic" or the "Company") Celtic enters into agreement to purchase concentrates Celtic is pleased to announce that it has entered into an agreement with asubsidiary of European Goldfields Limited, Hellas Gold S.A. ("Hellas Gold"), forthe purchase of 50,000 tonnes of concentrates containing approximately 30,000 ozof gold. As announced on 22 September 2006, the Company acquired 9,000 tonnes ofconcentrate containing approximately 6,000 oz of gold, to be processed on atrial basis, by Celtic at its Suzdal BIOX(R) plant in Kazakhstan. The Companyalso announced that, if the initial shipments proved successful, it intended topurchase up to an additional 120,000 tonnes of concentrates from Hellas Gold.The Company has been very satisfied by the results of the trial and is thereforeannouncing an agreement to purchase a further 50,000 tonnes of concentrates,with shipments expected to be completed by the end of September 2009. The Company operates the only BIOX(R) plant in the FSU for the treatment ofrefractory sulphide ores and in addition to treating ore produced at its Suzdalmine, it will be utilising available BIOX(R) capacity to produce more gold. Suzdal has produced over 28,599 oz of gold in the last three months, whichincludes 11,780 oz produced in September, at an average sale price of US$718 peroz. Kevin Foo, Managing Director of Celtic, said, "We have been delighted with theresults of our initial trial to process third party concentrates at our SuzdalBIOX(R) plant. This agreement is a significant step forward in our strategy tocapitalise on our technology advantages at Suzdal and we are also looking atother third party concentrate opportunities within Kazakhstan and Russia, asmany refractory gold ores remain unexploited." Contact information: Kevin Foo / Jonathan Scott-BarrettCeltic Resources Holdings PlcTel: + 44 (0)20 7921 8800Investors@celtic resources.com Leesa Peters / Jane StaceyConduit PRTel: +44 (0)20 7429 6606 / (0)792 292 3306leesa@conduitpr.com Anthony CardewCardew GroupTel: +44 (0)20 7930 0777anthony.cardew@cardewgroup.com Strand Partners LimitedSimon RaggettStuart FaulknerTel: +44 (0)20 7409 3494 About the Suzdal BIOX(R) plant: Celtic has successfully developed the first BIOX(R) plant for treatment ofrefractory sulphide ores in the FSU at its Suzdal mine in Kazakhstan. The plantuses a sulphide oxidation process for recovering gold from refractory ores orconcentrates. The process utilises a mixed population of naturally occurringbacteria, that are present in all sulphide ores, to break down the sulphidemineral matrix, thereby liberating the occluded gold for subsequent cyanidation. The BIOX(R) process acts as an alternative to conventional processes of roastingand pressure oxidation and offers advantages of reduced capital cost, simplicityof operations, robustness and very low environmental impact. Any person who is the holder of 1 per cent. or more of any class of shares inCeltic may be required to make disclosures pursuant to Rule 8.3 of the IrishTakeover Panel Act, 1997, Takeover Rules 2001 to 2006. The Directors of Celtic accept responsibility for the information contained inthis announcement and to the best of their knowledge and belief (having takenall reasonable care to ensure that such is the case), the information containedin this announcement is in accordance with the facts and, where appropriate,does not omit anything likely to affect the import of such information. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
22nd Apr 20247:00 amRNSTrading Update
13th Mar 20247:00 amRNSShare Purchase
13th Feb 20245:27 pmRNSTR-1 Notification
13th Feb 20245:22 pmRNSTR-1
1st Feb 20243:30 pmRNSResult of AGM
15th Dec 20234:15 pmRNSPosting of Annual Report and Notice of AGM
21st Nov 20235:34 pmRNSPDMR Shareholding
20th Nov 20237:00 amRNSFinal Results
17th Nov 20237:00 amRNSNotice of Results and Online Presentation
7th Nov 20237:00 amRNSLatest product release incorporates Generative AI
2nd Nov 20237:00 amRNSMajor new customer win with Tier-1 Telco
16th Oct 20237:00 amRNSTrading Update
25th Sep 202311:53 amRNSHolding(s) in Company
6th Jul 20237:00 amRNSCompletion of Initial Implementation at Telesur
21st Jun 20237:00 amRNSMajor new contract
22nd May 20237:00 amRNSGartner Market Guide Reports
15th May 20237:00 amRNSHalf-year Report
4th May 20237:00 amRNSDate of Interim Results and Investor Presentation
17th Apr 20237:00 amRNSH1 2023 Trading Update
31st Mar 20237:00 amRNSMajor New Contract
23rd Mar 20234:35 pmRNSPrice Monitoring Extension
14th Mar 20232:32 pmRNSHolding(s) in Company
21st Feb 20237:00 amRNSCompletion of Major Implementation
2nd Feb 20232:19 pmRNSResult of AGM
20th Jan 20234:40 pmRNSSecond Price Monitoring Extn
20th Jan 20234:35 pmRNSPrice Monitoring Extension
28th Dec 20227:00 amRNSGrant of Options and PDMR Shareholding
15th Dec 20225:20 pmRNSHolding(s) in Company
2nd Dec 20222:35 pmRNSHolding(s) in Company
30th Nov 20226:29 pmRNSPDMR and PCA shareholding
30th Nov 202211:18 amRNSHolding(s) in Company
28th Nov 20227:00 amRNSFinal Results
23rd Nov 20227:00 amRNSNotice of Results and Investor Presentation
2nd Nov 20225:49 pmRNSHolding(s) in Company
2nd Nov 202212:40 pmRNSHolding(s) in Company
26th Oct 20227:00 amRNSRelease of latest version of flagship product set
24th Oct 20227:00 amRNSTrading Update
6th Oct 20227:00 amRNSAppointment of Joint Broker
25th Aug 20223:48 pmRNSGrant of Options
8th Aug 20223:08 pmRNSHolding(s) in Company
28th Jul 20224:35 pmRNSPrice Monitoring Extension
19th Jul 20227:00 amRNSHolding(s) in Company
6th Jul 20227:00 amRNSMajor Contract Win
13th May 20227:33 amRNSDirector Share Purchase
9th May 20227:00 amRNSInterim Results Presentation
9th May 20227:00 amRNSInterim Results
25th Apr 202210:13 amRNSHolding(s) in Company
19th Apr 20227:00 amRNSH1 2022 Trading Update
6th Apr 20227:00 amRNSCerillion Client MVN-X Reaches Million Subscribers
7th Mar 20227:00 amRNSWins Prestigious Megabuyte Performance Award

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.